sibutramine and Body Weight studies

sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

Excerpt	Relevance	Reference
" The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate."	9.27	Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018)
"Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects."	9.16	Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012)
"12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0."	9.14	[Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity]. ( Ametov, AS; Vlasova, IuIu, 2010)
"Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients."	9.14	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010)
"To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)."	9.13	Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008)
"Body weight reduced in both groups but the reduction was greater with sibutramine (-15."	9.13	Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008)
"This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects."	9.12	A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007)
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial."	9.12	Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007)
" The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study."	9.11	Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004)
"To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)."	9.10	Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003)
"The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females."	9.10	Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002)
"Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function."	9.09	A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000)
"Obese patients with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) between 27 and 40 and a history of hypertension controlled with a calcium channel blocker (with or without concomitant thiazide diuretic treatment) were randomized to receive sibutramine (n = 150) or placebo (n = 74) with minimal behavioral intervention for 52 weeks."	9.09	Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000)
"After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight."	9.09	Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001)
"The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity."	9.09	Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001)
"In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels."	9.09	Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001)
" We have compared the novel (multiple monoamine neurotransmitter reuptake inhibitor) antiobesity drug sibutramine (10 mg once daily) with the extensively studied serotonin-releasing antiobesity agent dexfenfluramine (15 mg twice daily)."	9.08	A comparison of sibutramine and dexfenfluramine in the treatment of obesity. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998)
"The currently available drugs for long-term treatment of obesity are sibutramine and orlistat."	8.84	Currently available drugs for the treatment of obesity: Sibutramine and orlistat. ( Chaput, JP; St-Pierre, S; Tremblay, A, 2007)
"Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet."	8.81	The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002)
" In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks."	7.77	Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011)
"To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats."	7.74	Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008)
"Aim of the study was to examine the course of body weight and cardiovascular risk parameters under the everyday life conditions in general practice after obese patients had terminated their sibutramine treatment."	7.72	[Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004)
"We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones."	7.71	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001)
"Food intake and body weight decreased acutely in a dose-related manner in both groups with sibutramine treatment."	7.71	Regulation of body weight and carcass composition by sibutramine in rats. ( Camacho, R; Gorski, JN; Hickey, GJ; MacIntyre, DE; Murphy, B; Shu, J; Strack, AM, 2002)
"Chronic administration of sibutramine lowers body weight, presumably by altering brain monoamine metabolism."	7.70	Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. ( Dunn-Meynell, AA; Levin, BE, 2000)
"When the hypothalamic ventromedial nucleus and arcuate nucleus were destroyed in rats by treatment with monosodium glutamate in the neonatal stage, increase in the Lee index (body weight 1/3/body length) and in retroperitoneal fat as well as decreases in spontaneous motor activity, food consumption and growth hormone secretion function associated with hypothalamic low body length obesity (monosodium glutamate-treated obesity; MSG-OB) were observed as these rats grew."	7.70	Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. ( Gomita, Y; Nakagawa, T; Ohyama, T; Okamura, H; Ukai, K, 2000)
"Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment."	6.73	Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007)
"The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease."	6.71	The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004)
"Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats."	5.35	Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009)
"Sibutramine is a serotonin and norepinephrine reuptake intake inhibitor approved for the management of obesity."	5.35	Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. ( Lee, J; Lee, TS; Teoh, T, 2008)
" The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate."	5.27	Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018)
" This study compared the effectiveness of self-help cognitive-behavioral therapy (shCBT) and an anti-obesity medication (sibutramine), alone and in combination, and it is only the second placebo-controlled trial of any medication for BED to evaluate longer-term effects after treatment discontinuation."	5.19	Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. ( Barnes, RD; Garcia, R; Genao, I; Grilo, CM; Gueorguieva, R; Masheb, RM; McKenzie, KC; Walsh, BT; White, MA, 2014)
"Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects."	5.16	Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012)
"To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine."	5.16	Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. ( Brooke, A; Delafont, B; Elkhawad, M; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Tan, CY; Vidal-Puig, A; Virtue, S, 2012)
"The aim of the study was to evaluate the effects of 12-month treatment with sibutramine plus L-carnitine compared with sibutramine alone on body weight, glycemic control, insulin resistance, and inflammatory state in type 2 diabetes mellitus patients."	5.15	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2011)
"We observed a decrease of body weight after 9 and 12 months in the group treated with sibutramine, but not in the control group."	5.15	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2011)
"12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0."	5.14	[Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity]. ( Ametov, AS; Vlasova, IuIu, 2010)
"We used functional magnetic resonance imaging to explore brain responses to food images in overweight humans, examining independently the impact of a prescan meal ("satiety") and the anti-obesity drug sibutramine, a serotonin and noradrenaline reuptake inhibitor."	5.14	Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. ( Brooke, A; Bullmore, ET; Cambridge, VC; de Wit, S; Delafont, B; Farooqi, IS; Fletcher, PC; Miller, SR; Napolitano, A; Nathan, PJ; O'Rahilly, S; Skeggs, A, 2010)
"Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients."	5.14	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010)
"To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)."	5.13	Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008)
"Body weight reduced in both groups but the reduction was greater with sibutramine (-15."	5.13	Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008)
" We did not find any influence of 5% body weight loss induced by sibutramine on circulating levels of endocannabinoids and adipose-tissue expression of endocannabinoid genes in obese subjects."	5.13	Peripheral endocannabinoid system activity in patients treated with sibutramine. ( Bátkai, S; Engeli, S; Gorzelniak, K; Harvey-White, J; Heusser, K; Janke, J; Jordan, J; Luft, FC; Pacher, P, 2008)
"This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects."	5.12	A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007)
"Open-label sibutramine treatment decreased body weight 4."	5.12	Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. ( Diedrich, A; Engeli, S; Heusser, K; Janke, J; Jordan, J; Luft, FC; Tank, J; Wiesner, S, 2007)
"The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial."	5.12	Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007)
" The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study."	5.11	Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004)
"This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors."	5.11	Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005)
"After 6 months of sibutramine treatment statistically significant changes from baseline were observed for body weight (85."	5.11	Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. ( Chen, YC; Fan, SC; He, CT; Hsieh, CH; Hung, YJ; Kuo, SW; Lee, CH; Pei, D; Sheu, WH; Wu, LY, 2005)
"To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)."	5.10	Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003)
"Although antidepressants are the pharmacological agents most often studied in the treatment of binge-eating disorder (BED), preliminary evidence from an open trial suggests that the antiobesity agent sibutramine hydrochloride may be effective."	5.10	A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. ( Appolinario, JC; Bacaltchuk, J; Claudino, AM; Coutinho, W; Godoy-Matos, A; Morgan, C; Sichieri, R; Zanella, MT, 2003)
"To investigate whether the satiety-inducing agent sibutramine affected body weight and associated anthropometry in overweight and obese (body mass index (BMI) > 27) Type 2 diabetic patients on sulphonylurea therapy."	5.10	Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. ( Melchionda, N; Moreno-Carretero, E; Serrano-Rios, M, 2002)
"The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females."	5.10	Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002)
"Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function."	5.09	A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000)
"Obese patients with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) between 27 and 40 and a history of hypertension controlled with a calcium channel blocker (with or without concomitant thiazide diuretic treatment) were randomized to receive sibutramine (n = 150) or placebo (n = 74) with minimal behavioral intervention for 52 weeks."	5.09	Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000)
"After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight."	5.09	Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001)
"The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity."	5.09	Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001)
"In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels."	5.09	Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001)
" We have compared the novel (multiple monoamine neurotransmitter reuptake inhibitor) antiobesity drug sibutramine (10 mg once daily) with the extensively studied serotonin-releasing antiobesity agent dexfenfluramine (15 mg twice daily)."	5.08	A comparison of sibutramine and dexfenfluramine in the treatment of obesity. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998)
" Carriers of leptin gene mutations are able to normalize their body weight after daily subcutaneous leptin administration."	4.89	Treatment options for children with monogenic forms of obesity. ( Hainerová, IA; Lebl, J, 2013)
" Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss."	4.85	Effect of antiobesity medications in patients with type 2 diabetes mellitus. ( Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET, 2009)
"The currently available drugs for long-term treatment of obesity are sibutramine and orlistat."	4.84	Currently available drugs for the treatment of obesity: Sibutramine and orlistat. ( Chaput, JP; St-Pierre, S; Tremblay, A, 2007)
"Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria."	4.82	Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2003)
"Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria."	4.82	Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2004)
" The two available drugs, orlistat and sibutramine, are capable of reducing body weight by 10%."	4.82	[Pharmacotherapy of obesity]. ( Ludvik, B; Tripp, B, 2004)
"Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet."	4.81	The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002)
"Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day."	4.79	Sibutramine--a review of clinical efficacy. ( Lean, ME, 1997)
" Chronic administration of BI 186908 resulted in significant body weight reduction comparable to sibutramine in a 4 week diet-induced obesity model in rats."	3.81	Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. ( Arndt, K; Budzinski, R; Heckel, A; Kley, JT; Lehmann, T; Lenter, M; Lotz, RR; Maier, GM; Markert, M; Müller, S; Oost, T; Roth, GJ; Rudolf, K; Stenkamp, D; Thomas, L, 2015)
"Sibutramine is an anti-obesity agent that induces weight loss by selective inhibition of neuronal reuptake of serotonin and norepinephrine; however, it is associated with the risk of cardiovascular diseases (CVD), including heart attack and stroke."	3.77	Proteome changes in rat plasma in response to sibutramine. ( Choi, DK; Choi, JW; Joo, JI; Kim, DH; Oh, TS; Wang, X; Yun, JW, 2011)
" In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks."	3.77	Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011)
"To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats."	3.74	Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008)
"To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs."	3.74	Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. ( Elfhag, K; Finer, N; Rössner, S, 2008)
"The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice."	3.74	Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008)
" Sibutramine treatment did not affect the dietary behaviour of high-protein- or high-carbohydrate-fed rats, while it significantly attenuated the daily food intake and body weight gain rate in the high-fat group, at the dose of 10 mg/kg."	3.74	Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats. ( Couvari, E; Dontas, I; Galanopoulou, P; Liapi, C; Mavri, M; Perelas, A; Perrea, D; Stroubini, T; Trapali, M, 2008)
"Sibutramine reduced body weight regardless of basal blood pressure."	3.73	Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. ( Hauner, H; Jordan, J; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2005)
" The centrally acting antiobesity drug, sibutramine, was used as the reference comparator."	3.73	Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. ( Buschmann, H; Codony, X; Dordal, A; Fisas, A; Giraldo, J; Heal, D; Holenz, J; Mercé, R; Pauwels, PJ; Romero, G; Sørensen, RV; Vrang, N, 2006)
"Dexfenfluramine (DEX) and sibutramine (SIB) are effective antiobesity agents."	3.73	Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. ( Brune, ME; Bush, EN; Droz, BA; Fey, T; Jacobson, PB; Knourek-Segel, VE; Lin, E; Shapiro, R, 2006)
"Aim of the study was to examine the course of body weight and cardiovascular risk parameters under the everyday life conditions in general practice after obese patients had terminated their sibutramine treatment."	3.72	[Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004)
"We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones."	3.71	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001)
"Chronic administration of sibutramine lowers body weight, presumably by altering brain monoamine metabolism."	3.70	Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. ( Dunn-Meynell, AA; Levin, BE, 2000)
"When the hypothalamic ventromedial nucleus and arcuate nucleus were destroyed in rats by treatment with monosodium glutamate in the neonatal stage, increase in the Lee index (body weight 1/3/body length) and in retroperitoneal fat as well as decreases in spontaneous motor activity, food consumption and growth hormone secretion function associated with hypothalamic low body length obesity (monosodium glutamate-treated obesity; MSG-OB) were observed as these rats grew."	3.70	Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. ( Gomita, Y; Nakagawa, T; Ohyama, T; Okamura, H; Ukai, K, 2000)
"Childhood obesity is now considered to be an epidemic."	2.73	The effect of sibutramine on energy expenditure and body composition in obese adolescents. ( Delemarre-van de Waal, HA; Gerver, WJ; Kester, AD; Saris, WH; Van Mil, EG; Westerterp, KR, 2007)
"Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment."	2.73	Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007)
"Sibutramine was associated with significantly higher incidence of headache, dry mouth, constipation, insomnia, and dizziness."	2.73	Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. ( Berkowitz, RI; Blakesley, V; Crow, SJ; Hudson, JI; Mitchell, JE; Walsh, BT; Wilfley, DE, 2008)
"Sibutramine was effective only in A-allele carriers whereas GG genotypes showed no additional weight loss under sibutramine but showed the strongest increases in resting heart rate (8."	2.73	A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. ( Brockmeyer, N; Frey, UH; Hauner, H; Jöckel, KH; Manthey, I; Siffert, W, 2008)
"Sibutramine treatment raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs."	2.71	A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. ( McNulty, SJ; Ur, E; Williams, G, 2003)
"Sibutramine mono-therapy was significantly more effective in inducing BMI decrease compared with orlistat mono-therapy (p=0."	2.71	Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? ( Aydin, N; Dağar, A; Duman, C; Karasakal, M; Kaya, A; Topsever, P, 2004)
"The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease."	2.71	The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004)
"Adolescent obesity is becoming a health problem in both developed and developing countries."	2.71	Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. ( Appolinario, JC; Carraro, L; Coutinho, W; Godoy-Matos, A; Guedes, EP; Mattos, L; Moreira, RO; Oliveira, J; Rangel, C; Vieira, A, 2005)
"Sibutramine is a beta-phenethylamine which blocks reuptake of norepinephrine and serotonin."	2.68	A double-blind randomized placebo-controlled trial of sibutramine. ( Bray, GA; Cerise, F; Gordon, D; Heidingsfelder, S; Ryan, DH; Wilson, K, 1996)
"Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored."	2.55	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. ( De Vincentis, A; Derosa, G; Maffioli, P; Pedone, C; Picardi, A; Sahebkar, A; Vespasiani-Gentilucci, U, 2017)
"Obesity is a chronic metabolic disorder that affects one third of American adults."	2.44	Pharmacotherapy for obesity. ( Aronne, LJ; Neff, LM, 2007)
"The prevalence of obesity is growing at an alarming rate."	2.43	Obesity. ( Fabricatore, AN; Wadden, TA, 2006)
"Overweight and obesity have not only a significant psychological impact but also result in an increased risk for development of numerous chronic and sometimes fatal diseases."	2.41	Epidemiology, morbidity, and treatment of overweight and obesity. ( Aronne, LJ, 2001)
" The model could also be used to assess dose-response relationships."	1.38	Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model. ( Chan, LS; Kaptein, EM; Kaptein, JS, 2012)
"After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested."	1.37	Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. ( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011)
"Body weight was measured weekly, gastrocnemius muscle, perirenal, retroperitoneal and epididymal fat were isolated, fat/lean ratio was calculated and serum adiponectin and resistin were assayed."	1.35	Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. ( Dontas, I; Galanopoulou, P; Liapi, C; Perelas, A; Perrea, D; Stroubini, T; Tzavara, Ch, 2009)
"Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats."	1.35	Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009)
"Sibutramine is a serotonin and norepinephrine reuptake intake inhibitor approved for the management of obesity."	1.35	Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. ( Lee, J; Lee, TS; Teoh, T, 2008)
"Sibutramine has been described as an anti-obesity drug with the ability to inhibit serotonin (5-HT), noradrenaline, and dopamine re-uptake, but without affinity to histamine and muscarinic receptors."	1.33	Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors. ( Brum, C; Della Santa Rubio, A; Frassetto, SS; Khazzaka, M; Lopes, JJ; Pereira, P; Vinagre, AS, 2006)
"Sibutramine (10 mg/kg) was shown to consistently decrease carbohydrate and fat intake at all data points regardless of gender and diet."	1.32	Effect of sibutramine on macronutrient selection in male and female rats. ( LeBlanc, M; Thibault, L, 2003)

Research

Studies (108)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

BMI

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (5.56)	18.2507
2000's	76 (70.37)	29.6817
2010's	25 (23.15)	24.3611
2020's	1 (0.93)	2.80

Authors	Studies
Hertzog, DL	1
Al-Barazanji, KA	1
Bigham, EC	1
Bishop, MJ	1
Britt, CS	1
Carlton, DL	1
Cooper, JP	1
Daniels, AJ	1
Garrido, DM	1
Goetz, AS	1
Grizzle, MK	1
Guo, YC	1
Handlon, AL	1
Ignar, DM	1
Morgan, RO	1
Peat, AJ	1
Tavares, FX	1
Zhou, H	1
Mihalic, JT	1
Fan, P	1
Chen, X	2
Fu, Y	1
Motani, A	1
Liang, L	1
Lindstrom, M	1
Tang, L	1
Chen, JL	1
Jaen, J	1
Dai, K	1
Li, L	1
Oost, T	1
Heckel, A	1
Kley, JT	1
Lehmann, T	1
Müller, S	1
Roth, GJ	1
Rudolf, K	1
Arndt, K	1
Budzinski, R	1
Lenter, M	1
Lotz, RR	1
Maier, GM	1
Markert, M	1
Thomas, L	1
Stenkamp, D	1
Hansen, HH	1
Perens, J	1
Roostalu, U	1
Skytte, JL	1
Salinas, CG	1
Barkholt, P	1
Thorbek, DD	1
Rigbolt, KTG	1
Vrang, N	3
Jelsing, J	2
Hecksher-Sørensen, J	1
Dedov, II	1
Melnichenko, GA	1
Troshina, EA	1
Mazurina, NV	1
Galieva, MO	1
Hainerová, IA	2
Lebl, J	1
Borges, CS	1
Missassi, G	1
Pacini, ES	1
Kiguti, LR	1
Sanabria, M	1
Silva, RF	1
Banzato, TP	1
Perobelli, JE	1
Pupo, AS	1
Kempinas, WG	1
Grilo, CM	1
Masheb, RM	1
White, MA	1
Gueorguieva, R	1
Barnes, RD	1
Walsh, BT	2
McKenzie, KC	1
Genao, I	1
Garcia, R	1
De Vincentis, A	1
Pedone, C	1
Vespasiani-Gentilucci, U	1
Picardi, A	1
Derosa, G	4
Maffioli, P	4
Sahebkar, A	1
Roth, JD	1
Trevaskis, JL	1
Wilson, J	1
Lei, C	1
Athanacio, J	1
Mack, C	1
Kesty, NC	1
Coffey, T	1
Weyer, C	1
Parkes, DG	1
Choussein, S	1
Makri, AA	1
Frangos, CC	1
Petridou, ET	1
Daskalopoulou, SS	1
Stroubini, T	2
Perelas, A	2
Liapi, C	2
Perrea, D	2
Dontas, I	2
Tzavara, Ch	1
Galanopoulou, P	2
Oh, KS	1
Ryu, SY	1
Lee, S	1
Seo, HW	1
Oh, BK	1
Kim, YS	1
Lee, BH	1
Georgopoulos, NA	1
Katsikis, I	2
Florakis, D	2
Panidis, D	2
Kandarakis, ED	1
Fabricatore, AN	2
Wadden, TA	3
Moore, RH	1
Butryn, ML	1
Heymsfield, SB	1
Nguyen, AM	1
Tallett, AJ	1
Blundell, JE	1
Rodgers, RJ	1
Chudasama, HP	1
Bhatt, PA	1
Salvadeo, SA	1
Ferrari, I	3
Gravina, A	1
Mereu, R	1
D'Angelo, A	3
Palumbo, I	3
Randazzo, S	3
Cicero, AF	3
Nonogaki, K	1
Kaji, T	1
Frassetto, SS	2
Alves, IO	1
Santos, MM	1
Schmidt, AE	1
Lopes, JJ	2
Oliveira, PA	1
Vinagre, AS	2
Pereira, P	2
Vlasova, IuIu	1
Ametov, AS	1
Fletcher, PC	1
Napolitano, A	2
Skeggs, A	1
Miller, SR	2
Delafont, B	2
Cambridge, VC	1
de Wit, S	1
Nathan, PJ	1
Brooke, A	2
O'Rahilly, S	1
Farooqi, IS	1
Bullmore, ET	1
Choi, JW	1
Joo, JI	1
Kim, DH	1
Wang, X	1
Oh, TS	1
Choi, DK	1
Yun, JW	1
Li, M	1
Chang, B	1
Zhen, Z	1
Qin, PJ	1
Liu, WK	1
Tong, XL	1
Schindler, C	1
Chavakis, T	1
Lamounier-Zepter, V	1
Bornstein, SR	1
Coutinho, W	3
James, WP	1
Zamrazilová, H	1
Sedláčková, D	1
Hainer, V	2
Papazoglou, D	1
Restas, E	1
Papanas, N	1
Papatheodorou, K	1
Babouris, C	1
Glaros, D	1
Antonoglou, C	1
Maltezos, E	1
Guzmán, DC	1
García, EH	1
Mejía, GB	1
Olguín, HJ	1
Jiménez, FT	1
Soto, EB	1
Del Angel, DS	1
Aparicio, LC	1
Hansen, G	1
Murgatroyd, PR	1
Elkhawad, M	1
Tan, CY	1
Virtue, S	1
Vidal-Puig, A	1
Nunez, DJ	1
Kaptein, EM	1
Chan, LS	1
Kaptein, JS	1
McNulty, SJ	1
Ur, E	1
Williams, G	1
Wellman, PJ	1
Jones, SL	1
Miller, DK	1
Padwal, R	2
Li, SK	2
Lau, DC	2
Sabuncu, T	2
Harma, M	2
Nazligul, Y	1
Kilic, F	1
Appolinario, JC	2
Bacaltchuk, J	1
Sichieri, R	1
Claudino, AM	1
Godoy-Matos, A	2
Morgan, C	1
Zanella, MT	1
LeBlanc, M	1
Thibault, L	1
Aydin, N	1
Topsever, P	1
Kaya, A	1
Karasakal, M	1
Duman, C	1
Dağar, A	1
Wirth, A	2
Ucar, E	1
Birden, F	1
Yasar, O	1
Tripp, B	1
Ludvik, B	1
Carraro, L	1
Vieira, A	1
Oliveira, J	1
Guedes, EP	1
Mattos, L	1
Rangel, C	1
Moreira, RO	1
Tankova, T	1
Dakovska, G	1
Lazarova, M	1
Dakovska, L	1
Kirilov, G	1
Koev, D	1
Jordan, J	3
Scholze, J	2
Matiba, B	1
Hauner, H	2
Sharma, AM	1
Vettor, R	2
Serra, R	1
Fabris, R	2
Pagano, C	2
Federspil, G	2
Ferrer-Lorente, R	1
Cabot, C	1
Fernández-López, JA	1
Remesar, X	1
Alemany, M	1
Gaciong, Z	1
Placha, G	1
Redmon, JB	1
Reck, KP	1
Raatz, SK	1
Swanson, JE	1
Kwong, CA	1
Ji, H	1
Thomas, W	1
Bantle, JP	1
Hung, YJ	1
Chen, YC	1
Pei, D	1
Kuo, SW	1
Hsieh, CH	1
Wu, LY	1
He, CT	1
Lee, CH	1
Fan, SC	1
Sheu, WH	1
Cuppini, A	1
Matteini, P	1
Fisas, A	1
Codony, X	1
Romero, G	1
Dordal, A	1
Giraldo, J	1
Mercé, R	1
Holenz, J	1
Sørensen, RV	1
Heal, D	2
Buschmann, H	1
Pauwels, PJ	1
Bush, EN	1
Shapiro, R	1
Brune, ME	1
Knourek-Segel, VE	1
Droz, BA	1
Fey, T	1
Lin, E	1
Jacobson, PB	1
Kabrnova, K	1
Aldhoon, B	1
Kunesova, M	1
Wagenknecht, M	1
Henderson, DC	1
Fan, X	1
Copeland, PM	1
Borba, CP	1
Daley, TB	1
Nguyen, DD	1
Zhang, H	1
Hayden, D	1
Freudenreich, O	1
Cather, C	1
Evins, AE	1
Goff, DC	1
Van Mil, EG	1
Westerterp, KR	1
Kester, AD	1
Delemarre-van de Waal, HA	1
Gerver, WJ	1
Saris, WH	1
Chaput, JP	1
St-Pierre, S	2
Tremblay, A	2
Heusser, K	2
Engeli, S	2
Tank, J	1
Diedrich, A	1
Wiesner, S	1
Janke, J	2
Luft, FC	2
Grimm, E	1
Herrmann, D	1
Unger, T	1
Kintscher, U	1
Della Santa Rubio, A	1
Brum, C	1
Khazzaka, M	1
Elfhag, K	1
Finer, N	1
Rössner, S	1
Lindholm, Å	1
Bixo, M	1
Björn, I	1
Wölner-Hanssen, P	1
Eliasson, M	1
Larsson, A	1
Johnson, O	1
Poromaa, IS	1
Danielsson, P	1
Janson, A	1
Norgren, S	1
Marcus, C	1
Fernstrom, JD	1
Choi, S	1
Wilfley, DE	1
Crow, SJ	1
Hudson, JI	1
Mitchell, JE	1
Berkowitz, RI	2
Blakesley, V	1
Diamanti-Kandarakis, E	1
Nassis, GP	1
Karkanaki, A	1
Georgopoulos, N	1
Lee, J	1
Teoh, T	1
Lee, TS	1
Frey, UH	1
Jöckel, KH	1
Manthey, I	1
Brockmeyer, N	1
Siffert, W	1
Bahadori, B	1
Uitz, E	1
Tonninger-Bahadori, K	1
Moghadasian, MH	1
Gorzelniak, K	1
Bátkai, S	1
Pacher, P	1
Harvey-White, J	1
Neff, LM	1
Aronne, LJ	3
Mashiko, S	1
Ishihara, A	1
Iwaasa, H	1
Moriya, R	1
Kitazawa, H	1
Mitobe, Y	1
Ito, J	1
Gomori, A	1
Matsushita, H	1
Takahashi, T	1
MacNeil, DJ	1
Van der Ploeg, LH	1
Fukami, T	1
Kanatani, A	1
Trapali, M	1
Couvari, E	1
Mavri, M	1
Bray, GA	1
Ryan, DH	1
Gordon, D	1
Heidingsfelder, S	1
Cerise, F	1
Wilson, K	1
Lean, ME	1
Hanotin, C	1
Thomas, F	1
Jones, SP	1
Leutenegger, E	1
Drouin, P	1
Van Gaal, LF	1
Peiffer, FW	1
De Leeuw, IH	1
Kalia, M	1
O'Callaghan, JP	1
Miller, DB	1
Kramer, M	1
Fanghänel, G	2
Cortinas, L	2
Sánchez-Reyes, L	2
Berber, A	2
Kunt, T	1
Glick, SD	1
Haskew, RE	1
Maisonneuve, IM	1
Carlson, JN	1
Jerussi, TP	1
McMahon, FG	1
Fujioka, K	1
Singh, BN	1
Mendel, CM	2
Rowe, E	2
Rolston, K	1
Johnson, F	1
Mooradian, AD	1
Granzotto, M	1
Lombardi, AM	1
Ferretti, E	1
Marzolo, M	1
Scagnol, I	1
Womble, LG	1
Sarwer, DB	1
Arnold, ME	1
Steinberg, CM	1
Levin, BE	1
Dunn-Meynell, AA	1
Magnati, G	1
Dei Cas, A	1
Nakagawa, T	1
Ukai, K	1
Ohyama, T	1
Gomita, Y	1
Okamura, H	1
Keipes, M	1
Fuente Martinez, M	1
Nicolay, L	1
Kuffer, V	1
Mersch, L	1
Klees, J	1
Jacqué, M	1
Brown, M	1
Bing, C	1
King, P	1
Pickavance, L	1
Wilding, J	1
Smith, IG	1
Goulder, MA	1
Boozer, CN	1
Leibel, RL	1
Love, RJ	1
Cha, MC	1
Bérubé-Parent, S	1
Prud'homme, D	1
Doucet, E	1
Dujovne, CA	1
Zavoral, JH	1
Eisenberg, D	1
Serrano-Rios, M	1
Melchionda, N	1
Moreno-Carretero, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Treatment of Binge Eating in Obese Patients in Primary Care[NCT00537810]	Phase 4	104 participants (Actual)	Interventional	2007-09-30	Completed
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382]	Phase 3	60 participants (Anticipated)	Interventional	2008-11-30	Active, not recruiting
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder[NCT00402584]	Phase 3	304 participants (Actual)	Interventional	2000-08-31	Completed
Evaluation of the Effectiveness of Cryotherapy in Slimming of the Abdomen and Saddlebags[NCT04287153]		30 participants (Actual)	Interventional	2017-09-17	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

BMI (kg/m^2) was measured 4 months after treatment. (NCT00537810)
Timeframe: 4 months

Binge Eating (Remission)

Intervention	BMI (kg/m^2) (Mean)
Sibutramine	38.4
Placebo	39.6
Placebo/CBTsh	35.9
Sibutramine/CBTsh	35.6

Remission from binge eating (zero binge episodes during previous 28 days) (NCT00537810)
Timeframe: 4 months treatment; 6 and 12 month follow up post treatment

Article	Year
Treatment options for children with monogenic forms of obesity. World review of nutrition and dietetics, 2013, Volume: 106 Topics: Bariatric Surgery; Body Mass Index; Body Weight; Child; Cyclobutanes; Energy Metabolism; Heterozygot	2013
Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. Current pharmaceutical design, 2017, Volume: 23, Issue:6 Topics: Adiponectin; Anti-Obesity Agents; Body Mass Index; Body Weight; C-Reactive Protein; Cyclobutanes; Hu	2017
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabe	2009
[Pharmacological concepts for the treatment of obesity - a therapeutic meander?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:31-32 Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Body Weight; Brain; Combined Modality	2011
Long-term pharmacotherapy for obesity and overweight. The Cochrane database of systematic reviews, 2003, Issue:4 Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl	2003
Long-term pharmacotherapy for obesity and overweight. The Cochrane database of systematic reviews, 2004, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl	2004
[Pharmacotherapy of obesity]. Wiener medizinische Wochenschrift (1946), 2004, Volume: 154, Issue:13-14 Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus; Humans	2004
Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes care, 2005, Volume: 28, Issue:4 Topics: Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Randomized Contr	2005
[Obesity and metabolic syndrome: clinical and therapeutic review]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2005, Volume: 64, Issue:1 Topics: Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Diseases; Cyclobutanes; Exercise;	2005
Serotonin and norepinephrine reuptake inhibition and eating behavior. Annals of the New York Academy of Sciences, 2006, Volume: 1083 Topics: Abdominal Fat; Antidepressive Agents; Appetite Depressants; Body Weight; Cyclobutanes; Depression; E	2006
Currently available drugs for the treatment of obesity: Sibutramine and orlistat. Mini reviews in medicinal chemistry, 2007, Volume: 7, Issue:1 Topics: Anti-Obesity Agents; Body Weight; Cyclobutanes; Energy Metabolism; Exercise; Humans; Lactones; Obesi	2007
Obesity. Annual review of clinical psychology, 2006, Volume: 2 Topics: Appetite Depressants; Bariatric Surgery; Behavior Therapy; Body Mass Index; Body Weight; Chronic Dis	2006
The development of tolerance to drugs that suppress food intake. Pharmacology & therapeutics, 2008, Volume: 117, Issue:1 Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Huma	2008
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclo	2007
Sibutramine--a review of clinical efficacy. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21 Suppl 1 Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physio	1997
[SEEDO'2000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Española para el Estudio de la Obesidad]. Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15 Topics: Adolescent; Adult; Age Factors; Aged; Anti-Obesity Agents; Appetite Depressants; Biliopancreatic Div	2000
Epidemiology, morbidity, and treatment of overweight and obesity. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 23 Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Body Height; Body Mass Index; Body Weight;	2001
The discovery and status of sibutramine as an anti-obesity drug. European journal of pharmacology, 2002, Apr-12, Volume: 440, Issue:2-3 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobuta	2002

Article	Year
Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obesity facts, 2018, Volume: 11, Issue:4 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Female;	2018
Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behaviour research and therapy, 2014, Volume: 58 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Binge-Eating Disorder; Black or African American; Body	2014
Predictors of attrition and weight loss success: Results from a randomized controlled trial. Behaviour research and therapy, 2009, Volume: 47, Issue:8 Topics: Adult; Age Factors; Appetite Depressants; Body Weight; Combined Modality Therapy; Cyclobutanes; Depr	2009
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:3 Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; C-Reactive Protein; Carnitine; Cholesterol;	2011
[Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity]. Terapevticheskii arkhiv, 2010, Volume: 82, Issue:8 Topics: Adult; Anthropometry; Appetite Depressants; Body Composition; Body Weight; Combined Modality Therapy	2010
Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, Oct-27, Volume: 30, Issue:43 Topics: Adiposity; Adult; Amygdala; Appetite Depressants; Basal Ganglia; Body Weight; Brain; Cyclobutanes; D	2010
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:5 Topics: Adiponectin; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein;	2011
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2010, Volume: 13, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C	2010
Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. Genetic testing and molecular biomarkers, 2012, Volume: 16, Issue:2 Topics: Alleles; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Female;	2012
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:6 Topics: Absorptiometry, Photon; Adult; Appetite Depressants; Body Composition; Body Weight; Calorimetry, Ind	2012
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes care, 2003, Volume: 26, Issue:1 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cyclobutanes; Diabetes Mellitus; D	2003
Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertility and sterility, 2003, Volume: 80, Issue:5 Topics: Adult; Androgen Antagonists; Appetite Depressants; Blood Pressure; Body Constitution; Body Weight; C	2003
A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Archives of general psychiatry, 2003, Volume: 60, Issue:11 Topics: Adolescent; Adult; Antidepressive Agents; Appetite Depressants; Body Weight; Bulimia; Cyclobutanes;	2003
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? The Tohoku journal of experimental medicine, 2004, Volume: 202, Issue:3 Topics: Adult; Anthropometry; Anti-Obesity Agents; Body Mass Index; Body Weight; Combined Modality Therapy;	2004
The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes, nutrition & metabolism, 2004, Volume: 17, Issue:2 Topics: Adolescent; Adult; Appetite Depressants; Blood Glucose; Body Constitution; Body Mass Index; Body Wei	2004
Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:3 Topics: Adolescent; Appetite Depressants; Blood Pressure; Body Mass Index; Body Weight; Combined Modality Th	2005
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta diabetologica, 2004, Volume: 41, Issue:4 Topics: Adipose Tissue; Adult; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Diabetes Mell	2004
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. Journal of human hypertension, 2005, Volume: 19, Issue:9 Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia	2005
Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes care, 2005, Volume: 28, Issue:6 Topics: Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diabete	2005
Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8 Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cyc	2005
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta psychiatrica Scandinavica, 2007, Volume: 115, Issue:2 Topics: Adult; Anthropometry; Antipsychotic Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Bo	2007
The effect of sibutramine on energy expenditure and body composition in obese adolescents. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:4 Topics: Adolescent; Age Determination by Skeleton; Appetite Depressants; Blood Pressure; Body Composition; B	2007
Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:4 Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Body Weight; Cyclobutanes; Female; Hum	2007
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation, 2007, Apr-17, Volume: 115, Issue:15 Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane	2007
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertility and sterility, 2008, Volume: 89, Issue:5 Topics: Adolescent; Adult; Appetite Depressants; Body Weight; Cardiovascular Diseases; Cyclobutanes; Double-	2008
Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:11 Topics: Absorptiometry, Photon; Adolescent; Adult; Antidepressive Agents; Body Weight; Child; Child, Prescho	2007
Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. The American journal of psychiatry, 2008, Volume: 165, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Bu	2008
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. International journal of obesity (2005), 2008, Volume: 32, Issue:4 Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut	2008
A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. Pharmacogenetics and genomics, 2008, Volume: 18, Issue:2 Topics: Adult; Base Sequence; Body Weight; Chromogranins; Cyclobutanes; DNA Primers; Female; GTP-Binding Pro	2008
Peripheral endocannabinoid system activity in patients treated with sibutramine. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:5 Topics: Abdominal Fat; Adolescent; Adult; Appetite Depressants; Arachidonic Acids; Biopsy; Body Weight; Cann	2008
A double-blind randomized placebo-controlled trial of sibutramine. Obesity research, 1996, Volume: 4, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Body Weight; Combined Modality Ther	1996
A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obesity research, 1998, Volume: 6, Issue:4 Topics: Adult; Appetite Depressants; Body Constitution; Body Mass Index; Body Weight; Cyclobutanes; Dexfenfl	1998
A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2000, Volume: 24, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Appetite Depressants; Body Constitution; Body Mass In	2000
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of internal medicine, 2000, Jul-24, Volume: 160, Issue:14 Topics: Adult; Aged; Appetite Depressants; Black People; Body Weight; Cyclobutanes; Double-Blind Method; Fem	2000
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obesity research, 2000, Volume: 8, Issue:6 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Th	2000
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:5 Topics: Adolescent; Adult; Aged; Anthropometry; Appetite Depressants; Body Mass Index; Body Weight; Cross-Ov	2001
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. The Journal of family practice, 2001, Volume: 50, Issue:6 Topics: Adult; Aged; Appetite Depressants; Behavior Therapy; Body Mass Index; Body Weight; Combined Modality	2001
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. American heart journal, 2001, Volume: 142, Issue:3 Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Weight; Cyclobutanes; Double-Blind Method; Femal	2001
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:2 Topics: Appetite Depressants; Body Mass Index; Body Weight; Cholesterol; Cyclobutanes; Diabetes Mellitus; Di	2002
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, obesity & metabolism, 2002, Volume: 4, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo	2002
Elevated serum liver enzymes in obesity: a dilemma during clinical trials. International journal of obesity, 1991, Volume: 15, Issue:12 Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antidepressive Agents; Aspartate Aminotransferase	1991
Sibutramine in weight control: a dose-ranging, efficacy study. Clinical pharmacology and therapeutics, 1991, Volume: 50, Issue:3 Topics: Adult; Behavior Therapy; Body Weight; Cyclobutanes; Dose-Response Relationship, Drug; Double-Blind M	1991

Article	Year
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorganic & medicinal chemistry letters, 2006, Sep-15, Volume: 16, Issue:18 Topics: Animals; Body Weight; Mice; Mice, Inbred AKR; Models, Molecular; Molecular Structure; Pyrimidinones;	2006
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition. Bioorganic & medicinal chemistry letters, 2012, Jun-01, Volume: 22, Issue:11 Topics: Animals; Body Weight; Brain; Carbazoles; Cyclohexanecarboxylic Acids; Diet, High-Fat; Dogs; Drug Eva	2012
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. Bioorganic & medicinal chemistry letters, 2015, Aug-15, Volume: 25, Issue:16 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Drug Discovery; Ether	2015
Whole-brain activation signatures of weight-lowering drugs. Molecular metabolism, 2021, Volume: 47 Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Cyclobutanes; Homeostasis; Imaging, Three-Dimensio	2021
Slimmer or fertile? Pharmacological mechanisms involved in reduced sperm quality and fertility in rats exposed to the anorexigen sibutramine. PloS one, 2013, Volume: 8, Issue:6 Topics: Analysis of Variance; Animals; Appetite Depressants; Body Weight; Cyclobutanes; Fertility; Follicle	2013
Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. International journal of obesity (2005), 2008, Volume: 32, Issue:8 Topics: Amyloid; Animals; Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet; Disease Mo	2008
Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. Cytokine, 2009, Volume: 46, Issue:2 Topics: Adiponectin; Animals; Appetite Depressants; Body Composition; Body Weight; Cyclobutanes; Diet; Dieta	2009
Melanin-concentrating hormone-1 receptor antagonism and anti-obesity effects of ethanolic extract from Morus alba leaves in diet-induced obese mice. Journal of ethnopharmacology, 2009, Mar-18, Volume: 122, Issue:2 Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Calcium; CHO Cells; Cricetinae; Cricetulu	2009
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome. Fertility and sterility, 2009, Volume: 91, Issue:6 Topics: Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Female; Humans; Insulin Resistance	2009
Sibutramine & naloxone: infra-additive interaction in the regulation of appetite? Behavioural brain research, 2010, Feb-11, Volume: 207, Issue:1 Topics: Analysis of Variance; Animals; Appetite; Appetite Depressants; Behavior, Animal; Body Weight; Cyclob	2010
Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:11 Topics: Adiposity; Animals; Anti-Obesity Agents; Antidepressive Agents; Appetite Regulation; Blood Pressure;	2009
Hypothalamic orexin and pro-opiomelanocortin activities are essential for the anorexic effects of m-chlorophenylpiperazine in mice. The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:9 Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Eating; Hyperphagia; Hypothalamus; Intrace	2010
Absence of sibutramine effect on spontaneous anxiety in rats. Arquivos brasileiros de endocrinologia e metabologia, 2010, Volume: 54, Issue:4 Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anti-Obesity Agents; Anxiety; Body Weight; Cyclo	2010
Proteome changes in rat plasma in response to sibutramine. Proteomics, 2011, Volume: 11, Issue:7 Topics: Adipose Tissue; Animals; Appetite Depressants; Appetite Regulation; Blood Proteins; Body Weight; Car	2011
Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. The American journal of Chinese medicine, 2011, Volume: 39, Issue:2 Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Body Weight; Cholesterol; Cyclobutanes; Dietary Fats; D	2011
Sibutramine: balanced judgment or prejudice? Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2011, Volume: 33, Issue:2 Topics: Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Humans; Judgment; Obesity; Prejudic	2011
Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. Obesity facts, 2011, Volume: 4, Issue:4 Topics: Adult; Appetite Depressants; Body Composition; Body Weight; Cyclobutanes; Gonadotropins; Homozygote;	2011
Effect of sibutramine on 5-hydroxyindole acetic acid levels and selected oxidative biomarkers on brain regions of female rats in the presence of zinc. Basic & clinical pharmacology & toxicology, 2012, Volume: 110, Issue:5 Topics: Animals; Appetite Depressants; Biomarkers; Body Weight; Brain; Calcium; Cyclobutanes; Energy Intake;	2012
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta pharmacologica Sinica, 2012, Volume: 33, Issue:2 Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Eating; Glucagon-Like Peptide 1; Glucose To	2012
Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model. Eating and weight disorders : EWD, 2012, Volume: 17, Issue:4 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Mass Index; Body Weight; Cyclob	2012
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat. Pharmacology, biochemistry, and behavior, 2003, Volume: 75, Issue:1 Topics: Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Body Weight; Cyclobutanes;	2003
Effect of sibutramine on macronutrient selection in male and female rats. Physiology & behavior, 2003, Volume: 80, Issue:2-3 Topics: Animals; Body Weight; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Dose-Resp	2003
[Sustained weight reduction after cessation of obesity treatment with Sibutramine]. Deutsche medizinische Wochenschrift (1946), 2004, Apr-30, Volume: 129, Issue:18 Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobuta	2004
Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. International journal of obesity (2005), 2005, Volume: 29, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Pressure; Body Mass Ind	2005
Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats. European journal of pharmacology, 2005, Apr-25, Volume: 513, Issue:3 Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Dexfenfluramine; Drug Interactions; Drug Th	2005
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. British journal of pharmacology, 2006, Volume: 148, Issue:7 Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cell Line; Condition	2006
Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine, 2006, Volume: 29, Issue:2 Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Dexfenfluramine; Diet, Fat-Restricted; Ghre	2006
Locomotor and peripheral effects of sibutramine modulated by 5-HT2 receptors. Canadian journal of physiology and pharmacology, 2006, Volume: 84, Issue:12 Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Cyproheptadine; Diaphragm; Eating; Energy	2006
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Body Weight; Cyclobuta	2008
Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. Journal of psychosomatic research, 2008, Volume: 64, Issue:1 Topics: Adult; Antipsychotic Agents; Appetite Depressants; Body Image; Body Weight; Catatonia; Cyclobutanes;	2008
Successful treatment of a morbidly obese and growth-retarded adolescent with Williams-Beuren Syndrome by combining the medication of growth hormone and sibutramine. Singapore medical journal, 2008, Volume: 49, Issue:1 Topics: Adolescent; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Huma	2008
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:7 Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R	2008
Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats. Pharmacology, 2008, Volume: 82, Issue:1 Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Diet; Dietary Carbohydrates; Dietary Fats;	2008
New pharmacological directions for the treatment of overweight and obesity. Acta clinica Belgica, 1999, Volume: 54, Issue:3 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Enzyme Inhibi	1999
Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. Brain research, 2000, Mar-06, Volume: 858, Issue:1 Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Dexfenfluramine; Eating; Fluoxetine; Immun	2000
[Obesity: when does the internist recommend surgery?]. Zentralblatt fur Chirurgie, 2000, Volume: 125, Issue:3 Topics: Adult; Appetite Depressants; Body Weight; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity,	2000
Enantioselective behavioral effects of sibutramine metabolites. European journal of pharmacology, 2000, May-26, Volume: 397, Issue:1 Topics: Animals; Appetite Depressants; Behavior, Animal; Biogenic Monoamines; Body Weight; Cyclobutanes; Des	2000
Effect of sibutramine on glucose metabolism in genetically obese (fa/fa) Zucker rats. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2000, Volume: 24 Suppl 2 Topics: Animals; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Eating; Glucose Clamp Techn	2000
Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2000, Volume: 279, Issue:6 Topics: Adipose Tissue; Animals; Appetite Depressants; Arcuate Nucleus of Hypothalamus; Body Weight; Cyclobu	2000
Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations. Eating and weight disorders : EWD, 2000, Volume: 5, Issue:3 Topics: Appetite Depressants; Body Weight; Brain; Cyclobutanes; Energy Intake; Homeostasis; Humans; Leptin;	2000
Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Experimental animals, 2000, Volume: 49, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Adipose Tissue; Animals; Animals, Newborn; Appetite Depressants; Arc	2000
[Evolution and weight and body composition determination after therapy for pathological obesity for measuring compliance in (re)-education]. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2000, Issue:1 Topics: Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet, Reducing; Electric Impedance	2000
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. British journal of pharmacology, 2001, Volume: 132, Issue:8 Topics: Adipose Tissue; Animals; Appetite Depressants; Body Weight; Cyclobutanes; Diet; Feeding Behavior; Hy	2001
Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism: clinical and experimental, 2001, Volume: 50, Issue:8 Topics: Animals; Body Composition; Body Weight; Cyclobutanes; Diet; Drug Synergism; Energy Intake; Energy Me	2001
Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:8 Topics: Adult; Basal Metabolism; Blood Pressure; Body Weight; Cyclobutanes; Diet, Reducing; Energy Metabolis	2001
Risk factor modification through weight loss enhanced with pharmacotherapy. Current atherosclerosis reports, 2002, Volume: 4, Issue:1 Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Humans; Hyperlipidemias;	2002
Regulation of body weight and carcass composition by sibutramine in rats. Obesity research, 2002, Volume: 10, Issue:3 Topics: Adipose Tissue; Animals; Appetite Depressants; Body Composition; Body Weight; Cyclobutanes; Eating;	2002
Can drugs help you lose weight? Harvard heart letter : from Harvard Medical School, 2002, Volume: 12, Issue:7 Topics: Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Orlistat; Weight Loss	2002

sibutramine and Body Weight